US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Thornburg Multi Sector Bond ETF

25.73

+0.02000.08%

Post-market: 25.740.0150+0.06%16:04 EST

Volume:5.08K

Turnover:130.62K

Market Cap:78.46M

PE:- -

High:25.75

Open:25.72

Low:25.71

Close:25.71

52wk High:26.52

52wk Low:24.82

Shares:3.05M

Float Shares:3.05M

Volume Ratio:0.21

T/O Rate:0.17%

Dividend:1.08

Dividend Rate:4.19%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Press Release: Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TMB"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TMB\",,,,,undefined,":{"symbol":"TMB","market":"US","secType":"STK","nameCN":"Thornburg Multi Sector Bond ETF","latestPrice":25.725,"timestamp":1770411600000,"preClose":25.705,"halted":0,"volume":5077,"hourTrading":{"tag":"盘后","latestPrice":25.74,"preClose":25.725,"latestTime":"16:04 EST","volume":4,"amount":102.9,"timestamp":1770411884395,"change":0.015,"changeRate":0.000583,"amplitude":0},"delay":0,"changeRate":0.0007780587434352511,"floatShares":3050000,"shares":3050000,"eps":0,"marketStatus":"Market Closed","change":0.02,"latestTime":"02-06 16:00:00 EST","open":25.72,"high":25.75,"low":25.7098,"amount":130619.6261,"amplitude":0.001564,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":25.705,"sharesOutstanding":3050000,"nav":25.659549,"aum":78261625.17,"dividendRate":0.041936,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.74,"preClose":25.725,"latestTime":"16:04 EST","volume":4,"amount":102.9,"timestamp":1770411884395,"change":0.015,"changeRate":0.000583,"amplitude":0},"volumeRatio":0.207006},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TMB\",,,,,undefined,":{"symbol":"TMB","floatShares":3050000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.207006,"shares":3050000,"dividePrice":1.0788,"high":25.75,"amplitude":0.001564,"preClose":25.705,"low":25.7098,"week52Low":24.82,"pbRate":"--","week52High":26.52,"institutionHeld":0,"latestPrice":25.725,"eps":0,"divideRate":0.041936,"volume":5077,"delay":0,"ttmEps":0,"open":25.72,"prevYearClose":25.58,"prevWeekClose":25.6854,"prevMonthClose":25.6854,"prevQuarterClose":25.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TMB\",params:#limit:5,,,undefined,":[{"date":"2026-01-29","symbol":"TMB","amount":0.02183,"announcedDate":"2026-01-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-29","defaultRemindTime":1769697000000,"name":"Thornburg Multi Sector Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-30","payableDate":"2026-01-29","currency":"USD","dateTimestamp":1769662800000,"payDate":"2026-01-30"},{"date":"2025-12-30","symbol":"TMB","amount":0.17497,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Thornburg Multi Sector Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2025-12-31"},{"date":"2025-11-26","symbol":"TMB","amount":0.08421,"announcedDate":"2025-11-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-26","defaultRemindTime":1764167400000,"name":"Thornburg Multi Sector Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-28","payableDate":"2025-11-26","currency":"USD","dateTimestamp":1764133200000,"payDate":"2025-11-28"},{"date":"2025-10-30","symbol":"TMB","amount":0.10251,"announcedDate":"2025-10-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-30","defaultRemindTime":1761831000000,"name":"Thornburg Multi Sector Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-31","payableDate":"2025-10-30","currency":"USD","dateTimestamp":1761796800000,"payDate":"2025-10-31"},{"date":"2025-09-29","symbol":"TMB","amount":0.07853,"announcedDate":"2025-09-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-29","defaultRemindTime":1759152600000,"name":"Thornburg Multi Sector Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-29","currency":"USD","dateTimestamp":1759118400000,"payDate":"2025-09-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TMB\",market:\"US\",,,undefined,":[{"executeDate":"2025-02-27","recordDate":"2025-02-27","paymentDate":"2025-02-28","value":0.04477,"currency":"USD"},{"executeDate":"2025-03-28","recordDate":"2025-03-28","paymentDate":"2025-03-31","value":0.10883,"currency":"USD"},{"executeDate":"2025-04-29","recordDate":"2025-04-29","paymentDate":"2025-04-30","value":0.10444,"currency":"USD"},{"executeDate":"2025-05-29","recordDate":"2025-05-29","paymentDate":"2025-05-30","value":0.09174,"currency":"USD"},{"executeDate":"2025-06-27","recordDate":"2025-06-27","paymentDate":"2025-06-30","value":0.09338,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TMB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TMB\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583679215","title":"Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583679215","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583679215?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037000,"startTime":"0","endTime":"0","summary":"Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden. Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity and generally well-tolerated safety profile in patients with advanced solid tumors. Announced new preclinical data at SITC for masked T cell engager programs supporting best-in-class potential and showing efficient masking, potent anti-tumor activity and broad therapeutic index. Anticipate cash runway into the first quarter of 2027. WALTHAM, Mass., Nov. 13, 2025  -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSS","L","BK4232","BK4107","BK4113","ORR","XLO","BK4585","SITC","LENZ","BK4231","TMB","BK4022","BK4139","LU0210528500.USD","R","BK4588","BK4007","LU0053666078.USD","LU2487616109.SGD","BK4080","BK4539"],"gpt_icon":0},{"id":"2581628886","title":"Press Release: Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581628886","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581628886?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:05","pubTimestamp":1762524300,"startTime":"0","endTime":"0","summary":"40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden . Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need. \"These compelling new Phase 2 data for vilastobart in combination with atezolizumab demonstrated a 40% objective response rate in heavily pre-pretreated patients with MSS mCRC without liver metastases and with high plasma TMB, signifying an important advance in our understanding of response to novel immunotherapy in MSS mCRC,\" said Katarina Luptakova, M.D., chief medical officer of Xilio. \"In addition, these data showed a statistically significant correlation between plasma-based TMB and response. We estimate that approximately 55% of patients with MSS CRC have high plasma TMB, representing a meaningful patient population who could ultimately benefit from combination treatment with vilastobart and a substantially greater prevalence of patients w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B12V2V27.USD","BK1541","BK4080","BK4007","BK4107","LU1023057109.AUD","BK4022","LU2487616109.SGD","01308","LU0053666078.USD","LU0210528500.USD","SG9999011746.SGD","BK4571","BK4588","BK4139","IE0003851619.USD","TMB","BK4535","IE00BYTNYN87.SGD","LU0359202008.SGD","BK1103","BK4108","BK4565","BK4552","BK4113","LENZ","BK4231","BK4548","LU0359201612.USD","ORR","IE00BYQNZ168.SGD","LU0456842615.SGD","SITC","MSS","BK4509","IE0003795394.USD","L","TME","BK4531","BK4232","R","XLO","01698","BK4585","BK4539","LU2039709279.SGD","BK4563","BK4526"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TMB\",params:#limit:6,delay:false,,,undefined,":[]}}